303963-92-0 Usage
General Description
(3aR,6aR)-6-((tert-butyldiphenylsilyloxy)methyl)-2,2-dimethyl-3aH-cyclopenta[d][1,3]dioxol-4(6aH)-one is a chemical compound that belongs to the class of cyclopentane compounds. It is a derivative of cyclopentadioxolone, with a tert-butyldiphenylsilyloxy substituent attached to the carbon atom. (3aR,6aR)-6-((tert-butyldiphenylsilyloxy)methyl)-2,2-dimethyl-3aH-cyclopenta[d][1,3]dioxol-4(6aH)-one is commonly used as a building block in organic synthesis, especially in the production of pharmaceuticals and other complex organic molecules. The tert-butyldiphenylsilyloxy group serves as a protecting group, which can be removed under specific conditions to reveal the reactive functionality of the compound. As a result, this compound is valuable for the synthesis of various biologically active compounds and has found applications in medicinal chemistry and drug discovery.
Check Digit Verification of cas no
The CAS Registry Mumber 303963-92-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,0,3,9,6 and 3 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 303963-92:
(8*3)+(7*0)+(6*3)+(5*9)+(4*6)+(3*3)+(2*9)+(1*2)=140
140 % 10 = 0
So 303963-92-0 is a valid CAS Registry Number.
InChI:InChI=1/C25H30O4Si/c1-24(2,3)30(19-12-8-6-9-13-19,20-14-10-7-11-15-20)27-17-18-16-21(26)23-22(18)28-25(4,5)29-23/h6-16,22-23H,17H2,1-5H3/t22-,23+/m1/s1
303963-92-0Relevant articles and documents
POLYMORPHIC COMPOUNDS AND USES THEREOF
-
, (2020/04/10)
The present invention provides compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.
Compounds and methods for treating neurological and cardiovascular conditions
-
, (2017/11/09)
The present invention relates to compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.
Synthesis, activity and metabolic stability of non-ribose containing inhibitors of histone methyltransferase DOT1L
Deng, Lisheng,Zhang, Li,Yao, Yuan,Wang, Cong,Redell, Michele S.,Dong, Shuo,Song, Yongcheng
, p. 822 - 826 (2013/08/26)
Histone methyltransferase DOT1L is a drug target for MLL leukemia. We report an efficient synthesis of a cyclopentane-containing compound that potently and selectively inhibits DOT1L (Ki = 1.1 nM) as well as H3K79 methylation (IC50 ~